期刊
JOURNAL OF IMMUNOLOGY
卷 181, 期 10, 页码 7273-7283出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.181.10.7273
关键词
-
类别
资金
- Jubilaumsfonds of the Austrian National Bank [10934, 11967]
- Austrian Science Fund (FWF) [P19424-B05]
- Ph.D. Program Molecular Medicine of the Medical University of Graz, Graz, Austria
- Austrian Science Fund (FWF) [P19424] Funding Source: Austrian Science Fund (FWF)
The accumulation of eosinophils in lung tissue is a hallmark of asthma, and it is believed that eosinophils play a crucial pathogenic role in allergic inflammation. Prostaglandin (PG) E-2 exerts anti-inflammatory and bronchoprotective mechanisms in asthma, but the underlying mechanisms have remained unclear. In this study we show that PGE(2) potently inhibits the chemotaxis of purified human eosinophils toward eotaxin, PGD(2), and C5a. Activated monocytes similarly attenuated eosinophil migration, and this was reversed after pretreatment of the monocytes with a cyclooxygenase inhibitor. The selective E-prostanoid (EP) 2 receptor agonist butaprost mimicked the inhibitory effect of PGE, on eosinophil migration, whereas an EP2 antagonist completely prevented this effect. Butaprost, and also PGE(2). inhibited the C5a-induced degranulation of eosinophils. Moreover, selective kinase inhibitors revealed that the inhibitory effect of PGE(2) on eosinophil migration depended upon activation of PI3K and protein kinase C, but not cAMP. In animal models, the EP2 agonist butaprost inhibited the rapid mobilization of eosinophils from bone marrow of the in situ perfused guinea pig hind limb and prevented the allergen-induced bronchial accumulation of eosinophils in OVA-sensitized mice. Immunostaining showed that human eosinophils express EP2 receptors and that EP2 receptor expression in the murine lungs is prominent in airway epithelium and, after allergen challenge, in peribronchial infiltrating leukocytes. In summary, these data show that EP2 receptor agonists potently inhibit eosinophil trafficking and activation and might hence be a useful therapeutic option in eosinophilic diseases. The Journal of Immunology, 2008, 181: 7273-7283.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据